Homo sapiens
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA271881 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Mitotically associated long non-coding RNA, MANCR regulates cell cycle in triple negative breast cancer cells
| PRJNA396880 | ENA
Project description:Long non-coding RNA landscape of patients biopsies from advanced Triple Negative Breast Cancer
| PRJNA734951 | ENA
Project description:The development of triple-negative breast cancers (TNBCs) – a subset of tumors with particularly aggressive pathogenesis – is critically regulated by certain tumor-microenvironment-associated cells called mesenchymal stem/stromal cells (MSCs), which we and others have shown promote TNBC progression by activating a multitude of signaling nodes that propagate malignant traits in neighboring cancer cells. Characterization of these signaling cascades will better our understanding of TNBC biology, and stands to bring about novel therapeutics that can eliminate the morbidity and mortality associated with advanced disease. Here, we particularly focused on an emerging family of non-coding RNAs – called long non-coding RNAs or lncRNAs – and utilized a MSC-supported TNBC progression model to identify specific lncRNAs of functional relevance to TNBC pathogenesis. We used Affymetrix arrays to identify the gene expression changes that breast cancer cells (in this case, MDA-MB-231 cells) exhibit as they interact with admixed human MSCs
2021-06-09 | GSE171121 | GEO
Project description:Selective expression of long non-coding RNAs in a breast cancer cell progression model
| PRJNA384982 | ENA
Project description:Triple negative breast cancer is a heterogeneous disease with distinct molecular subtypes that differentially respond to chemotherapy and targeted agents. The purpose of this study was to explore the clinical relevance of Lehmann triple negative breast cancer subtypes by identifying any differences in response to neoadjuvant chemotherapy among them.
2017-11-17 | GSE106977 | GEO
Project description:Addressing tumor heterogeneity in breast cancer research is crucial, given the distinct subtypes like triple-negative, luminal A/B, and HER2, requiring precise differentiation for effective treatment. This study introduces a non-invasive method by analyzing post-translationally modified proteins in plasma extracellular vesicles (EVs), which play a role in immune regulation and intercellular communication. Examining modifications like phosphorylation, acetylation, and glycosylation in EVs provides insights into breast cancer dynamics. One hundred one plasma samples from luminal A/B, triple-negative breast cancer, and healthy individuals underwent discovery and validation experiments. The study identified over 28,000 unique non-modified peptides, 5,000 phosphopeptides, 680 acetyl peptides, and 1,300 glycopeptides that were successfully characterized. Bioinformatics analyses revealed significant overexpression of 815 non-modified proteins, 3,958 phosphopeptides, 352 acetyl peptides, and 895 glycopeptides in luminal A/B or triple-negative breast cancer subtypes. Phosphorylated and glycosylated PD-L1 peptides emerged as potential markers for breast cancer, regardless of subtype. Aligning findings with literature and PAM50 gene signatures highlighted markers correlated with lower survival rates. The study also conducted 123 scheduled parallel reaction monitoring (PRM) analyses, leveraging machine learning to pinpoint a panel of specific modification sites with high accuracy in subtype differentiation. This research reveals diagnostic markers and enhances understanding of the molecular landscape, contributing to more effective and personalized breast cancer diagnostics and treatments.
2025-11-01 | PXD057412 | JPOST Repository
Project description:Identification of differentially expressed long non-coding RNAs in bladder cancer
| PRJNA239575 | ENA